Lodz

• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended recruitment
  2023-506525-11-00 5 2021-04-19 Primary Membranous Nephropathy (pMN)
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit … Ended recruitment
  2023-509066-38-00 4 2021-04-16 Atrial Fibrillation
• Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV Vaccine Ended recruitment
  2022-500256-37-00 5 2021-04-08 Prevention of persistent anogenital HPV infection and disease caused b
• A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t … Ended recruitment
  2023-509759-15-00 5 2021-03-15 atopic dermatitis
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat … Ended recruitment
  2023-507695-52-00 5 2021-03-05 Mantle cell lymphoma
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• An extension study to learn if Zilucoplan is safe and works over a long period in adult participants with generalized myasthenia gravis. Ended recruitment
  2024-512399-37-00 5 2020-12-29 Generalized Myasthenia Gravis
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended recruitment
  2023-505852-23-00 5 2020-11-12 High risk recurrent prostate cancer previously treated with radical pr
• Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub … Ended recruitment
  2023-508281-15-00 1 2020-11-10 Locally Advanced or Metastatic Solid Tumors
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended recruitment
  2023-506467-34-00 5 2020-10-20 Relapsing Multiple Sclerosis (MS)
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex … Ended recruitment
  2023-506877-37-00 5 2020-09-28 Relapsed/Refractory Multiple Myeloma
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended recruitment
  2022-502746-27-00 5 2020-08-21 Endometrial Cancer
• PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro … Ended recruitment
  2024-515953-52-00 5 2020-07-24 Post-Essential Thrombocythaemia Myelofibrosis
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended recruitment
  2023-507419-37-00 5 2020-06-25 Plasma cell myeloma

Showing 601–624 of 898 trials